CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-461

Although, this might be a bit too conservative to be honest. Whilst the ASX is known for mispricing stocks, several examples (eg PME) show that the ASX will still give high valuations to those companies that deserve them, and will maintain them so long as the company continues to deliver strongly. EYE is clearly moving quickly into this category of a high quality growing company, and so I see no reason the ASX also won't give this a proper multiple soon.

Considering that peers in the MIGS space were fetching valuations over 50x sales during their initial high growth stages, this indicates an equivalent valuation of over $5 for EYE, based on the current fundamentals. Let's see if this market will price this fairly, based on equivalent peer valuations.

Exciting stuff, looking forward to the results later this month. Not sure when the rerate will happen, but when it does happen it'll have to be very large to account for all the progress that has been made (and begin to price in future growth as well)